Erin R. Lepper

Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Antoinette R. Tan, Xiaowei Yang, Stephen M. Hewitt et al. · Journal of Clinical Oncology · 2004 · 176 citations

Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes

Ron H.J. Mathijssen, Floris A. de Jong, Ron H. N. van Schaik et al. · JNCI Journal of the National Cancer Institute · 2004 · 124 citations · Full text

Effect of Common<i>CYP3A4</i>and<i>CYP3A5</i>Variants on the Pharmacokinetics of the Cytochrome<i>P</i>450 3A Phenotyping Probe Midazolam in Cancer Patients

Erin R. Lepper, Sharyn D. Baker, Matt Permenter et al. · Clinical Cancer Research · 2005 · 71 citations · Full text

Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor

Erin R. Lepper, Sandra M. Swain, Antoinette R. Tan et al. · Journal of Chromatography B · 2003 · 52 citations

Liquid-chromatographic Determination, Medicine, Receptor Tyrosine Kinase +4

Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors

Erin R. Lepper, Sylvia S. W. Ng, Michael Gütschow et al. · Journal of Medicinal Chemistry · 2004 · 49 citations